Company Description
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.
It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.
The company was incorporated in 2010 and is based in Redwood City, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Nov 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 228 |
| CEO | Dennis Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 United States | |
| Phone | 650 649 3530 |
| Website | coherus.com |
Stock Details
| Ticker Symbol | CHRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001512762 |
| CUSIP Number | 19249H103 |
| ISIN Number | US19249H1032 |
| Employer ID | 27-3615821 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dennis M. Lanfear | Chairman, President and Chief Executive Officer |
| Bryan J. McMichael | Chief Financial Officer |
| Paul Reider | Chief Commercial Officer |
| Richard L. Hameister | Chief Technical Officer |
| Jodi Sievers | Vice President of Investor Relations and Corporate Communications |
| Andy Rittenberg | Executive Vice President of General Counsel |
| Scott Saywell | Executive Vice President of Corporate Development |
| Rebecca Sunshine | Chief Human Resources Officer |
| Michael Chen | Senior Vice President of Commercial Analytics and Trade |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 28, 2025 | DEFM14A | Filing |
| Jan 14, 2025 | PREM14A | Filing |